These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

179 related articles for article (PubMed ID: 31730160)

  • 1. In vitro antimicrobial combination testing of and evolution of resistance to the first-in-class spiropyrimidinetrione zoliflodacin combined with six therapeutically relevant antimicrobials for Neisseria gonorrhoeae.
    Foerster S; Drusano G; Golparian D; Neely M; Piddock LJV; Alirol E; Unemo M
    J Antimicrob Chemother; 2019 Dec; 74(12):3521-3529. PubMed ID: 31730160
    [TBL] [Abstract][Full Text] [Related]  

  • 2. High susceptibility to zoliflodacin and conserved target (GyrB) for zoliflodacin among 1209 consecutive clinical Neisseria gonorrhoeae isolates from 25 European countries, 2018.
    Unemo M; Ahlstrand J; Sánchez-Busó L; Day M; Aanensen D; Golparian D; Jacobsson S; Cole MJ;
    J Antimicrob Chemother; 2021 Apr; 76(5):1221-1228. PubMed ID: 33564854
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacodynamics of zoliflodacin plus doxycycline combination therapy against
    Jacobsson S; Golparian D; Oxelbark J; Kong FYS; Da Costa RMA; Franceschi F; Brown D; Louie A; Drusano G; Unemo M
    Front Pharmacol; 2023; 14():1291885. PubMed ID: 38130409
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Using a public database of Neisseria gonorrhoeae genomes to detect mutations associated with zoliflodacin resistance.
    Adamson PC; Lin EY; Ha SM; Klausner JD
    J Antimicrob Chemother; 2021 Oct; 76(11):2847-2849. PubMed ID: 34324655
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Susceptibility Trends of Zoliflodacin against Multidrug-Resistant
    Le W; Su X; Lou X; Li X; Gong X; Wang B; Genco CA; Mueller JP; Rice PA
    Antimicrob Agents Chemother; 2021 Feb; 65(3):. PubMed ID: 33318010
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Gonococcal resistance to zoliflodacin could emerge via transformation from commensal Neisseria species. An in-vitro transformation study.
    Abdellati S; Laumen JGE; de Block T; De Baetselier I; Van Den Bossche D; Van Dijck C; Manoharan-Basil SS; Kenyon C
    Sci Rep; 2024 Jan; 14(1):1179. PubMed ID: 38216602
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Assessing novel partner antimicrobials to protect ceftriaxone against gonococcal resistance: An in vitro evaluation.
    Abdellati S; Gestels Z; Baranchyk Y; de Block T; Van Den Bossche D; De Baetselier I; Manoharan-Basil SS; Kenyon C
    Int J STD AIDS; 2024 Nov; 35(13):1042-1049. PubMed ID: 39226039
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High in vitro susceptibility to the novel spiropyrimidinetrione ETX0914 (AZD0914) among 873 contemporary clinical Neisseria gonorrhoeae isolates from 21 European countries from 2012 to 2014.
    Unemo M; Ringlander J; Wiggins C; Fredlund H; Jacobsson S; Cole M
    Antimicrob Agents Chemother; 2015 Sep; 59(9):5220-5. PubMed ID: 26077246
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Time-kill curve analysis and pharmacodynamic modelling for in vitro evaluation of antimicrobials against Neisseria gonorrhoeae.
    Foerster S; Unemo M; Hathaway LJ; Low N; Althaus CL
    BMC Microbiol; 2016 Sep; 16():216. PubMed ID: 27639378
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Interactions between Zoliflodacin and
    Collins JA; Basarab GS; Chibale K; Osheroff N
    ACS Infect Dis; 2024 Aug; 10(8):3071-3082. PubMed ID: 39082980
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Pharmacodynamic Evaluation of Dosing, Bacterial Kill, and Resistance Suppression for Zoliflodacin Against
    Jacobsson S; Golparian D; Oxelbark J; Alirol E; Franceschi F; Gustafsson TN; Brown D; Louie A; Drusano G; Unemo M
    Front Pharmacol; 2021; 12():682135. PubMed ID: 34093206
    [TBL] [Abstract][Full Text] [Related]  

  • 12. In vitro growth of multidrug-resistant Neisseria gonorrhoeae isolates is inhibited by ETX0914, a novel spiropyrimidinetrione.
    Papp JR; Lawrence K; Sharpe S; Mueller J; Kirkcaldy RD
    Int J Antimicrob Agents; 2016 Sep; 48(3):328-30. PubMed ID: 27499432
    [TBL] [Abstract][Full Text] [Related]  

  • 13. GyrB in silico mining in 27 151 global gonococcal genomes from 1928-2021 combined with zoliflodacin in vitro testing of 71 international gonococcal isolates with different GyrB, ParC and ParE substitutions confirms high susceptibility.
    Golparian D; Jacobsson S; Sánchez-Busó L; Bazzo ML; Lan PT; Galarza P; Ohnishi M; Unemo M
    J Antimicrob Chemother; 2022 Dec; 78(1):150-154. PubMed ID: 36308328
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Antimicrobial resistance in Neisseria gonorrhoeae isolates and gonorrhoea treatment in the Republic of Belarus, Eastern Europe, 2009-2019.
    Aniskevich A; Shimanskaya I; Boiko I; Golubovskaya T; Golparian D; Stanislavova I; Jacobsson S; Adaskevich A; Unemo M
    BMC Infect Dis; 2021 Jun; 21(1):520. PubMed ID: 34078300
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Zoliflodacin: An Oral Spiropyrimidinetrione Antibiotic for the Treatment of
    Bradford PA; Miller AA; O'Donnell J; Mueller JP
    ACS Infect Dis; 2020 Jun; 6(6):1332-1345. PubMed ID: 32329999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antimicrobial Resistance in Neisseria gonorrhoeae and Treatment of Gonorrhea.
    Unemo M; Golparian D; Eyre DW
    Methods Mol Biol; 2019; 1997():37-58. PubMed ID: 31119616
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Evaluating the potency of zoliflodacin against Helicobacter pylori: In vitro activity and conserved GyrB target.
    Liu J; Jia J; Shi T; Bai Y; Huang Y; Zeng L; Bi H
    Helicobacter; 2024; 29(2):e13075. PubMed ID: 38627919
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy of Zoliflodacin, a Spiropyrimidinetrione Antibiotic, Against Gram-Negative Pathogens.
    Oyardi O; Yilmaz FN; Dosler S
    Curr Microbiol; 2024 Jun; 81(8):241. PubMed ID: 38910195
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High in vitro activity of a novel dual bacterial topoisomerase inhibitor of the ATPase activities of GyrB and ParE (VT12-008911) against Neisseria gonorrhoeae isolates with various high-level antimicrobial resistance and multidrug resistance.
    Jeverica S; Golparian D; Hanzelka B; Fowlie AJ; Matičič M; Unemo M
    J Antimicrob Chemother; 2014 Jul; 69(7):1866-72. PubMed ID: 24651828
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Current and future antimicrobial treatment of gonorrhoea - the rapidly evolving Neisseria gonorrhoeae continues to challenge.
    Unemo M
    BMC Infect Dis; 2015 Aug; 15():364. PubMed ID: 26293005
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.